High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1
Jennifer L. Schehr(University of Wisconsin–Madison), Joshua M. Lang(University of Wisconsin–Madison), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Jay W. Warrick(University of Wisconsin–Madison), Zachery D. Schultz(University of Wisconsin–Madison), Erika Héninger(University of Wisconsin Carbone Cancer Center), Anwaar Saeed(University of Pittsburgh), Hannah M. Pezzi(University of Wisconsin–Madison), Jamie M. Sperger(University of Wisconsin–Madison), David J. Guckenberger(University of Wisconsin–Madison), Toby C. Campbell(University of Wisconsin–Madison), Kara Mattox(University of Wisconsin–Madison), David J. Beebe(University of Wisconsin–Madison), Scott M. Berry(John Innes Centre), Anne M. Traynor(University of Wisconsin Carbone Cancer Center)
Cited by 63
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k